These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20184286)

  • 1. [Antioxidant activity of cytoflavin in experimental diffuse purulent peritonitis].
    Kosinets VA
    Eksp Klin Farmakol; 2010 Jan; 73(1):30-2. PubMed ID: 20184286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Free-radical oxidation in liver during experimental widespread purulent peritonitis].
    Kosinets VA; Iarotskaia NN
    Eksp Klin Farmakol; 2012; 75(10):37-41. PubMed ID: 23240157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correction of bioenergetic processes in small intestine during experimental widespread purulent peritonitis].
    Kosinets VA
    Eksp Klin Farmakol; 2012; 75(8):39-43. PubMed ID: 23012995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correction of protein-lipid composition in liver mitochondria during experimental widespread purulent peritonitis].
    Kosinets VA; Osochuk SS; Iarotskaia NN
    Eksp Klin Farmakol; 2012; 75(3):31-4. PubMed ID: 22679751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological correction of free radical disturbances and endotoxicosis in patients with diffuse peritonitis at the postoperative period].
    Bagnenko SF; Mirzabaev AT; Batotsyrenov BV; Gorbachev NB; Miroshnichenko VN; Batotsyrenova KhV; Velikiĭ KF
    Vestn Khir Im I I Grek; 2011; 170(5):14-6, 18. PubMed ID: 22238957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardioprotective effect of cytoflavine on a model of doxorubicin-induced cardiomyopathy].
    Kashuro VA; Glushkov SI; Novikova TM; Aksenov VV
    Eksp Klin Farmakol; 2010 Mar; 73(3):15-7. PubMed ID: 20408423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An influence of cytoflavin on oxidative stress and activity of Na/K-ATPase of erythrocytes after brain trauma].
    Deriugina AV; Shumilova AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):51-55. PubMed ID: 29265087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antioxidant and membranoprotector treatment of chronic pyelonephritis].
    Gordiushina IV; Savchenko RP; Sukhanov DS; Petrov AIu; Romantsov MG
    Eksp Klin Farmakol; 2011; 74(4):27-30. PubMed ID: 21678656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effect of cytoflavin and its components in mice with acute alloxan intoxication].
    Volchegorskiĭ IA; Rassokhina LM; Ermakova SG; Miroshnichenko IIu
    Eksp Klin Farmakol; 2013; 76(4):26-31. PubMed ID: 23762986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic immunocorrection treatment of experimental widespread purulent peritonitis].
    Gostishchev VK; Kosinets VA; Matusevich EA; Adamenko GP
    Eksp Klin Farmakol; 2012; 75(2):42-6. PubMed ID: 22550860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroprotective effect of cytoflavin in closed craniocerebral trauma].
    Bul'on VV; Zarubina IV; Kovalenko AL; Alekseeva LE; Sapronov NS
    Eksp Klin Farmakol; 2003; 66(6):56-8. PubMed ID: 14743715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of cytoflavin and cardioxipin on the indices of lipid peroxidation and antioxidant protection in the blood of rat with dyslipidemia].
    Vodop'ianova OA; Moiseeva IIa; Rodina OP; Kustikova IN; Antropova NV
    Eksp Klin Farmakol; 2014; 77(6):27-9. PubMed ID: 25102732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenetic correction of metabolic disturbances in chronic liver affections].
    Romantsov MG; Petrov AIu; Aleksandrova LN; Sukhanov DS; Kovalenko AL
    Antibiot Khimioter; 2012; 57(11-12):33-41. PubMed ID: 23700935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of cytoflavin for the treatment of chronic brucellosis].
    Shul'diakov AA; Liapina EP; Soboleva LA; Reshetnikov AA; Zubareva EV; Trubetskov AD; Anashchenko AV; Evdokimov AV
    Klin Med (Mosk); 2011; 89(2):56-8. PubMed ID: 21574446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of reamberin for correction of enterocyte functional activity in experimental disseminated purulent peritonitis].
    Kosinets VA
    Eksp Klin Farmakol; 2010 Feb; 73(2):35-8. PubMed ID: 20369600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positive effect of cytoflavin on metabolic status changes in patients with burn disorder].
    Polutova NV; Ostrovskiĭ NV; Romantsov MG; Chesnokova NP
    Eksp Klin Farmakol; 2011; 74(7):33-7. PubMed ID: 21894767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Using cytoflavin for correcting x-ray contrasting agent-induced nephropathy].
    Karpishchenko SN; Zheregelia SN; Glushkov SI
    Eksp Klin Farmakol; 2010 Oct; 73(10):40-2. PubMed ID: 21254514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of cytoflavin in sports nutrition].
    Kosinets VA; Stolbitskiĭ VV; Shturich IP
    Klin Med (Mosk); 2012; 90(7):56-8. PubMed ID: 23019978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of cytoflavin in the treatment of chronic cerebral ischemia].
    Suslina ZA; Klocheva EG; Piradov MA; Rumiantseva SA; Romantsov MG; Kovalenko AL
    Klin Med (Mosk); 2010; 88(3):50-3. PubMed ID: 20608066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EFFECT OF CITOFLAVIN ON THE PARAMETERS OF LIPID PEROXIDATION IN BLOOD PLASMA OF RATS UNDER COLD STRESS CONDITIONS.].
    Dorovskikh VA; Li ON; Simonova NV; Shtarberg MA
    Eksp Klin Farmakol; 2016; 79(7):29-34. PubMed ID: 29782743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.